JIANGSU NHWA PHARMACEUTICAL CO., LTD |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 24.81 CNY | +3.94% |
|
+6.57% | -8.52% |
| 04-25 | Jiangsu Nhwa Pharmaceutical Co., LTD Approves Cash Dividend for 2023 | CI |
| 04-19 | Jiangsu Nhwa Pharmaceutical Co., LTD Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 11,855 | 16,092 | 15,769 | 24,736 | 27,326 | 24,998 | - | - |
| Enterprise Value (EV) 1 | 10,073 | 14,728 | 14,224 | 23,255 | 25,243 | 21,957 | 21,006 | 19,887 |
| P/E ratio | 17.6 x | 22.2 x | 19.8 x | 27.6 x | 26.3 x | 20.3 x | 16.2 x | 13.6 x |
| Yield | 0.86% | 0.63% | 1.28% | 0.81% | 1.18% | 0.72% | 0.85% | 0.96% |
| Capitalization / Revenue | 2.86 x | 4.79 x | 4.01 x | 5.75 x | 5.42 x | 4.19 x | 3.48 x | 2.94 x |
| EV / Revenue | 2.43 x | 4.38 x | 3.61 x | 5.41 x | 5.01 x | 3.68 x | 2.93 x | 2.34 x |
| EV / EBITDA | 11.7 x | 15.4 x | 13.7 x | 20.5 x | 19 x | 15.2 x | 11.6 x | 9.12 x |
| EV / FCF | - | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - | - |
| Price to Book | 3.28 x | 3.92 x | 3.2 x | 4.4 x | 4.25 x | 3.4 x | 2.86 x | 2.47 x |
| Nbr of stocks (in thousands) | 1,019,388 | 1,007,663 | 1,007,588 | 1,007,588 | 1,007,588 | 1,007,588 | - | - |
| Reference price 2 | 11.63 | 15.97 | 15.65 | 24.55 | 27.12 | 24.81 | 24.81 | 24.81 |
| Announcement Date | 26/02/20 | 26/02/21 | 25/02/22 | 27/02/23 | 29/03/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 4,149 | 3,361 | 3,936 | 4,299 | 5,042 | 5,961 | 7,178 | 8,503 |
| EBITDA 1 | 860.8 | 955.5 | 1,041 | 1,132 | 1,328 | 1,447 | 1,812 | 2,180 |
| EBIT 1 | 770.8 | 856.2 | 925.9 | 1,003 | 1,182 | 1,385 | 1,744 | 2,080 |
| Operating Margin | 18.58% | 25.47% | 23.53% | 23.34% | 23.45% | 23.23% | 24.29% | 24.46% |
| Earnings before Tax (EBT) 1 | 767.1 | 850.5 | 915.8 | 989.9 | 1,169 | 1,390 | 1,733 | 2,066 |
| Net income 1 | 663.3 | 728.3 | 797.8 | 900.9 | 1,037 | 1,234 | 1,542 | 1,835 |
| Net margin | 15.99% | 21.67% | 20.27% | 20.96% | 20.57% | 20.71% | 21.48% | 21.58% |
| EPS 2 | 0.6600 | 0.7200 | 0.7900 | 0.8900 | 1.030 | 1.225 | 1.530 | 1.824 |
| Free Cash Flow | - | - | - | - | - | - | - | - |
| FCF margin | - | - | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | 0.1000 | 0.1000 | 0.2000 | 0.2000 | 0.3200 | 0.1788 | 0.2114 | 0.2387 |
| Announcement Date | 26/02/20 | 26/02/21 | 25/02/22 | 27/02/23 | 29/03/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 1,044 | 992.6 | 1,009 | 1,119 | 1,178 | 1,179 | 1,222 | 1,256 | 1,386 | 1,358 | 1,389 | 1,457 | 1,647 | 1,613 | 1,715 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | 145.2 | 209.7 | 304.9 | 334.3 | 154.6 | 261.6 | 364.5 | 379.4 | 176.9 | 304.9 | 410.4 | 426.3 | 199.1 | 501.1 | - |
| Operating Margin | 13.91% | 21.13% | 30.24% | 29.87% | 13.12% | 22.19% | 29.84% | 30.21% | 12.77% | 22.46% | 29.54% | 29.26% | 12.09% | 31.08% | - |
| Earnings before Tax (EBT) | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EPS 2 | 0.1200 | 0.1900 | 0.2500 | 0.3000 | 0.1500 | 0.2300 | 0.3100 | 0.3400 | 0.1500 | 0.2600 | 0.3600 | 0.3800 | 0.2200 | 0.4500 | - |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 25/02/22 | 22/04/22 | 29/07/22 | 26/10/22 | 27/02/23 | 13/04/23 | 30/07/23 | 25/10/23 | 29/03/24 | 19/04/24 | - | - | - | - | - |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | 1,783 | 1,364 | 1,544 | 1,481 | 2,083 | 3,041 | 3,993 | 5,111 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - | - |
| ROE (net income / shareholders' equity) | 20.2% | 18.3% | 17.6% | 17.2% | 17.3% | 17% | 17.9% | 18.3% |
| ROA (Net income/ Total Assets) | 16.1% | 16.3% | 15.2% | - | - | 15.3% | 15.9% | 15.9% |
| Assets 1 | 4,116 | 4,472 | 5,242 | - | - | 8,079 | 9,696 | 11,538 |
| Book Value Per Share 2 | 3.550 | 4.080 | 4.890 | 5.580 | 6.390 | 7.300 | 8.680 | 10.00 |
| Cash Flow per Share 2 | 0.3000 | 1.240 | 0.7000 | 0.8500 | 1.000 | 1.140 | 1.350 | 1.520 |
| Capex 1 | 160 | 268 | 206 | 328 | 373 | 450 | 369 | 357 |
| Capex / Sales | 3.86% | 7.99% | 5.23% | 7.62% | 7.39% | 7.56% | 5.14% | 4.19% |
| Announcement Date | 26/02/20 | 26/02/21 | 25/02/22 | 27/02/23 | 29/03/24 | - | - | - |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
24.81
CNY
Average target price
32.21
CNY
Spread / Average Target
+29.81%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -8.52% | 3.45B | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- 002262 Stock
- Financials Jiangsu Nhwa Pharmaceutical Co., LTD
